Medical Sciences Company, Medlab Clincial (ASX:MDC) has received a license to export Cannabis from the office of Drug Control (ODC) as it relates to 2 pioneering cannabis based medicines.
Both of the products utilize Medlab's patented Nanocelle delivery platform.
The export license comes after the University of Sydney's Nano Institute validated the science behind the Nanocelle delivery platform,
CEO, Sean Hall says the export license allows Medlab to undertake more trade conversations with confidence in the knowledge that the company can legally supply overseas.
Shares in Medlab (ASX:MDC) closed 4.26 per cent lower to 45 cents yesterday